Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Ascending Dose Study of KER-050 (elritercept) in Lower-Risk Myelodysplastic Syndromes
2021-001838-19Phase 2Active
- Sponsor
- Keros Therapeutics
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elritercept in myelodysplastic syndrome (MDS) and anemia of myelodysplastic syndromes, sponsored by Keros Therapeutics. Primary endpoint: Primary endpoint (Part 1 and Part 2). Started Sep 2021; status: active.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)anemia of myelodysplastic syndromes
Beyond the preview
Go deeper on 2021-001838-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001838-19.